Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Fig. 4

SNAI2 expression correlates with progression-free survival (PFS) in patients with estrogen receptor (ER)+ metastatic breast cancer treated with endocrine therapy. Kaplan-Meier plots evaluating PFS according to expression of SNAI2 in ER+ metastatic lesions from a an initial and b a second cohort of patients with breast cancer treated with endocrine therapy in the advanced setting. c Survival analysis of PFS according to SNAI2 levels in fulvestrant-treated patients from cohorts 1 and 2. A two-sided p value (*p < 0.05) was calculated using log-rank testing. Representative micrographs of breast cancer metastasis sections showing low SNAI2 expression (d and e) or high SNAI2 expression (f and g) (× 20 magnification)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us